EP3814326A4 - Dihydropyrimidinderivate und verwendungen davon in der behandlung von hbv-infektion oder von hbv-induzierten erkrankungen - Google Patents

Dihydropyrimidinderivate und verwendungen davon in der behandlung von hbv-infektion oder von hbv-induzierten erkrankungen Download PDF

Info

Publication number
EP3814326A4
EP3814326A4 EP19825897.2A EP19825897A EP3814326A4 EP 3814326 A4 EP3814326 A4 EP 3814326A4 EP 19825897 A EP19825897 A EP 19825897A EP 3814326 A4 EP3814326 A4 EP 3814326A4
Authority
EP
European Patent Office
Prior art keywords
hbv
dihydropyrimide
derivatives
treatment
induced disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19825897.2A
Other languages
English (en)
French (fr)
Other versions
EP3814326A1 (de
Inventor
Gang Deng
Yimin Jiang
Qian Liu
Chao Liang
Zhao-Kui Wan
Wing Shun CHEUNG
Zhanling CHENG
Yanping Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Sciences Ireland ULC
Original Assignee
Janssen Sciences Ireland ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland ULC filed Critical Janssen Sciences Ireland ULC
Publication of EP3814326A1 publication Critical patent/EP3814326A1/de
Publication of EP3814326A4 publication Critical patent/EP3814326A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP19825897.2A 2018-06-26 2019-06-25 Dihydropyrimidinderivate und verwendungen davon in der behandlung von hbv-infektion oder von hbv-induzierten erkrankungen Withdrawn EP3814326A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018092875 2018-06-26
US201862716823P 2018-08-09 2018-08-09
PCT/CN2019/092857 WO2020001448A1 (en) 2018-06-26 2019-06-25 Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases

Publications (2)

Publication Number Publication Date
EP3814326A1 EP3814326A1 (de) 2021-05-05
EP3814326A4 true EP3814326A4 (de) 2022-03-16

Family

ID=68984711

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19825897.2A Withdrawn EP3814326A4 (de) 2018-06-26 2019-06-25 Dihydropyrimidinderivate und verwendungen davon in der behandlung von hbv-infektion oder von hbv-induzierten erkrankungen

Country Status (8)

Country Link
EP (1) EP3814326A4 (de)
JP (1) JP2021529188A (de)
KR (1) KR20210025596A (de)
CN (1) CN112513017A (de)
AU (1) AU2019296117A1 (de)
CA (1) CA3099605A1 (de)
MA (1) MA53023A (de)
WO (1) WO2020001448A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
AU2018291688B2 (en) 2017-06-27 2022-02-03 Janssen Pharmaceutica Nv Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections
US11053235B2 (en) * 2018-08-09 2021-07-06 Janssen Sciences Ireland Unlimited Company Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
CN114989097A (zh) * 2022-05-20 2022-09-02 无锡捷化医药科技有限公司 一种5-氨基-6-氯嘧啶-4-羧酸乙酯的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014029193A1 (en) * 2012-08-24 2014-02-27 Sunshine Lake Pharma Co., Ltd. Dihydropyrimidine compounds and their application in pharmaceuticals

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179131B2 (en) * 2015-07-13 2019-01-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
AU2018291688B2 (en) * 2017-06-27 2022-02-03 Janssen Pharmaceutica Nv Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014029193A1 (en) * 2012-08-24 2014-02-27 Sunshine Lake Pharma Co., Ltd. Dihydropyrimidine compounds and their application in pharmaceuticals

Also Published As

Publication number Publication date
CA3099605A1 (en) 2020-01-02
KR20210025596A (ko) 2021-03-09
JP2021529188A (ja) 2021-10-28
WO2020001448A1 (en) 2020-01-02
CN112513017A (zh) 2021-03-16
AU2019296117A1 (en) 2020-11-26
MA53023A (fr) 2021-05-05
EP3814326A1 (de) 2021-05-05

Similar Documents

Publication Publication Date Title
IL280483A (en) Muscle targeting complexes and uses thereof for treating pompe disease
EP4230133C0 (de) Kontrollierte und präzise behandlung von herzgeweben
LT3672954T (lt) Junginiai, jų druskos ir jų naudojimas ligoms gydyti
EP3600374C0 (de) Behandlung von atemwegsinfektion
EP3814326A4 (de) Dihydropyrimidinderivate und verwendungen davon in der behandlung von hbv-infektion oder von hbv-induzierten erkrankungen
EP3290514C0 (de) Anwendung von pi4kiii.alpha-protein und zugehöriger membranproteinkomplex in der behandlung von morbus alzheimer
IL280475A (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
EP3537982A4 (de) Kontrollierte behandlung von gewebe und dynamische wechselwirkung mit und vergleich von gewebe- und/oder behandlungsdaten
IL269083A (en) Methods for preventing and treating heart disease
EP3541401A4 (de) Behandlung von atemwegserkrankungen und -infektionen mit glutathionzusammensetzungen
EP3740282C0 (de) Metallothionein inhibitoren zur behandlung von diabetes, hepatitis und/oder entzündlicher lebererkrankung
EP3903796C0 (de) Pharmazeutische zusammensetzung und herstellungsverfahren dafür und verwendung davon zur behandlung von herzversagen
EP4094754C0 (de) Zusammensetzungen zur behandlung und/oder prävention von proteinaggregationserkrankungen
EP3641545A4 (de) Zusammensetzungen und verfahren damit zur behandlung von neurodegenerativer und mitochondrialer erkrankung
EP3558293C0 (de) Niedermolekulare inhibitore der sox-18-aktivität zur behandlung von angiogenese- und/oder lymphangiogenesebezogenen erkrankungen
EP3709969C0 (de) Emulsionen zur topischen behandlung von dermalen infektionen und schleimhautinfektionen
IL264407A (en) Novel application of gzd824 and pharmaceutically acceptable salts thereof in treating diseases
KR20240101580A9 (ko) Hbv 치료를 위한 약학 조합물
EP3463469C0 (de) Kombination von ledipasvir und sofosbuvir zur verwendung in der behandlung von hepatitis b infektionen beim mensch
EP3432898A4 (de) Behandlung von hauterkrankungen und krankheiten im zusammenhang mit mikrobiellen biofilmen
EP3790866A4 (de) Dihydropyrimidinderivate und verwendungen davon in der behandlung von hbv-infektion oder von hbv-induzierten erkrankungen
EP3610879A4 (de) Zusammensetzung zur behandlung und/oder vorbeugung von alzheimer-krankheit
EP3458045A4 (de) Behandlung der menière-krankheit
EP3703753A4 (de) Behandlung von ige-vermittelten allergischen erkrankungen
EP3703820A4 (de) Verwendung von mir101 oder mir128 bei der behandlung von anfallserkrankungen

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210126

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07D0239220000

Ipc: C07D0417140000

A4 Supplementary search report drawn up and despatched

Effective date: 20220216

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/20 20060101ALI20220210BHEP

Ipc: A61K 31/506 20060101ALI20220210BHEP

Ipc: C07D 417/14 20060101AFI20220210BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20221214

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230425